RZ-001

Small molecule

RRznomics, Inc.

RZ-001 is one of 66 small molecule programs targeting Hepatocellular Carcinoma. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatocellular CarcinomaActive, not recruiting

GlioblastomaActive, not recruiting

Hepatocellular CarcinomaPhase 1/Phase 2

Active, not recruiting

GlioblastomaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

797 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

Cysteine Hydrochloride

Novartis

Preclinical

1 2

Hepsera

Coreg

2 4

Apatinib

LLaNova Medicines Zhejiang Co., Ltd.

Preclinical

16 5

Doptelet

AAkarx

Preclinical

1 6

Miraclid

TTechpool Bio-Pharma Co., Ltd.

Preclinical

1 7

Vermox

WWim Janssens

Preclinical

1 8

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 9

Statin

Bristol-Myers Squibb

Preclinical

1 10

PD-1 Inhibitors

BBioNTech US Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1/2Recruiting

Hepatocellular Carcinoma

NCT06695026

Q2 2029

Phase 1/2Recruiting

Glioblastoma

NCT06102525

Phase 1/2Active, not recruiting

Hepatocellular Carcinoma

NCT05595473

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma2 trials

A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 in Combination With Valganciclovir (VGCV) and Atezolizumab/Bevacizumab in Subjects With Hepatocellular Carcinoma

Recruiting·RRznomics, Inc.·Phase 1/2·NCT06695026·45 enrolled

A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 with Valganciclovir (VGCV) in Subjects with Hepatocellular Carcinoma

Active, not recruiting·RRznomics, Inc.·Phase 1/2·NCT05595473·42 enrolled

Glioblastoma1 trial

A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Glioblastoma

Recruiting·RRznomics, Inc.·Phase 1/2·NCT06102525·43 enrolled

GBM1 trial

Expanded Access Program for GBM Subjects

Available·RRznomics, Inc.··NCT06676891

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for RZ-001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RZ-001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RZ-001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Rznomics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: RRznomics, Inc.

RZ-001

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q2 2029

Trials by Indication[1]

Hepatocellular Carcinoma2 trials

Glioblastoma1 trial

GBM1 trial

References

Drug Info

Quick Facts

Related News